Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
ACS Appl Mater Interfaces ; 12(6): 6876-6884, 2020 Feb 12.
Artigo em Inglês | MEDLINE | ID: mdl-31950828

RESUMO

Dengue virus (DENV) is a major infectious viral pathogen that affects millions of individuals worldwide every year, causing a potentially fatal syndrome, while no commercial antiviral drugs are yet available. To develop an antiviral against dengue fever, it is necessary to understand the relationship between DENV and host cells, which could provide a basis for viral dynamics and identification of inhibitory drug targets. In this study, we designed DiD-loaded and BODIPY-ceramide-encapsulated DENV-polymersome hybrid nanovesicles (DENVSomes) prepared by an extrusion method, which trigger red fluorescence in the endosome and green in the Golgi. DENVSome monitors the dynamics of host cell-virus interaction and tracking in living cells with novel state-of-the-art imaging technologies that show images at high resolution. Also, DENVSome can be exploited to screen whether candidate antiviral drugs interact with DENVs. Consequently, we successfully demonstrated that DENVSome is an efficient tool for tracking and unraveling the mechanisms of replication and drug screening for antiviral drugs of DENV.


Assuntos
Antivirais/farmacologia , Vírus da Dengue/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos/métodos , Compostos de Boro/química , Rastreamento de Células , Dengue/virologia , Vírus da Dengue/química , Vírus da Dengue/fisiologia , Avaliação Pré-Clínica de Medicamentos/instrumentação , Corantes Fluorescentes/química , Humanos , Nanopartículas/química , Replicação Viral/efeitos dos fármacos
2.
Adv Healthc Mater ; 8(2): e1800953, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30549426

RESUMO

Powerful adjuvants to augment vaccine efficacy with a less immunogenic vaccine system are in great demand. In this study, a novel squalene-based cationic poly(amino acid) adjuvant (CASq) that elicits both cellular (Th1) and humoral (Th2) immune responses is developed. CASq is demonstrated to promote cellular uptake of viral antigen and stimulate macrophages, leading to active production of interleukin-12. Furthermore, co-administration of inactivated pdm H1N1 vaccine with CASq significantly increases the generation of antigen-specific antibodies and T cell immune responses in mice, as well as resulting in complete prevention of disease symptoms and protection against lethal infection.


Assuntos
Adjuvantes Imunológicos/química , Adjuvantes Imunológicos/farmacologia , Vacinas contra Influenza/imunologia , Infecções por Orthomyxoviridae/imunologia , Polímeros/química , Animais , Citocinas/metabolismo , Imunidade Celular , Imunidade Humoral , Vírus da Influenza A Subtipo H1N1/imunologia , Vacinas contra Influenza/farmacologia , Lisina/química , Camundongos , Camundongos Endogâmicos C57BL , Nanopartículas/química , Infecções por Orthomyxoviridae/prevenção & controle , Fenilalanina/química , Polímeros/farmacologia , Células RAW 264.7 , Esqualeno/química , Vacinas de Produtos Inativados/imunologia , Vacinas de Produtos Inativados/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA